Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > Perspective

<< Previous

Bullboard Posts

Next >>

Comment by Strodon Nov 10, 2010 3:43am

262 Views

Post# 17685023

RE: Perspective

Very modestly put, but yes I do facking agree!! I've backed the truck up the last couple of months and have no intention of selling any time soon. The uranium sector is the next to make serious returns and this little puppy has been seriously undervalued even by uranium sector standards. I genuinely see 0.50s but obviously do not know when.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features